Chemours (CC) Liabilities and Shareholders Equity (2014 - 2026)

Chemours' Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $7.3 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 1.48% year-over-year to $7.3 billion; the TTM figure through Mar 2026 stood at $29.7 billion (changed 0.23% YoY), while the FY2025 annual figure was $7.4 billion, down 1.69% from the prior year.
• Liabilities and Shareholders Equity was $7.3 billion for Q1 2026 at Chemours, down from $7.4 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $8.2 billion in Q4 2023 to a low of $7.2 billion in Q2 2024.
• Historically, Liabilities and Shareholders Equity has averaged $7.6 billion across 5 years, with a median of $7.5 billion in 2025.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity rose 7.87% in 2023, then dropped 8.88% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $7.6 billion in 2022, then gained by 7.87% to $8.2 billion in 2023, then slipped by 8.88% to $7.5 billion in 2024, then declined by 1.69% to $7.4 billion in 2025, then dropped by 1.56% to $7.3 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $7.3 billion (Q1 2026), $7.4 billion (Q4 2025), and $7.5 billion (Q3 2025), per Business Quant data.